These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16924447)

  • 1. [Age-related macular degeneration: a socioeconomic time bomb in our aging society].
    Schrader WF
    Ophthalmologe; 2006 Sep; 103(9):742-8. PubMed ID: 16924447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].
    Pauleikhoff D; Scheider A; Wiedmann P; Gelisken F; Scholl HP; Roider I; Mohr A; Zlateva G; Xu X
    Ophthalmologe; 2009 Mar; 106(3):242-51. PubMed ID: 18709375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns and Health Care Costs for Age-Related Macular Degeneration in Japan: An Analysis of National Insurance Claims Data.
    Kume A; Ohshiro T; Sakurada Y; Kikushima W; Yoneyama S; Kashiwagi K
    Ophthalmology; 2016 Jun; 123(6):1263-8. PubMed ID: 26927204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL; Yu F
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of illness of neovascular age-related macular degeneration in Canada.
    Cruess A; Zlateva G; Xu X; Rochon S
    Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An epidemiological study of neovascular age-related macular degeneration in Germany.
    Krause L; Yousif T; Pohl K;
    Curr Med Res Opin; 2013 Oct; 29(10):1391-7. PubMed ID: 23944372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related macular degeneration: economic burden and value-based medicine analysis.
    Brown MM; Brown GC; Stein JD; Roth Z; Campanella J; Beauchamp GR
    Can J Ophthalmol; 2005 Jun; 40(3):277-87. PubMed ID: 15947797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary].
    Gibbert J; Müller D; Fauser S; Stock S
    Ophthalmologe; 2013 Jun; 110(6):528-36. PubMed ID: 23297119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.
    Bandello F; Augustin A; Sahel JA; Benhaddi H; Negrini C; Hieke K; Berdeaux GH;
    Drugs Aging; 2008; 25(3):255-68. PubMed ID: 18331076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.
    Gehrs KM; Anderson DH; Johnson LV; Hageman GS
    Ann Med; 2006; 38(7):450-71. PubMed ID: 17101537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.
    Tamura H; Goto R; Akune Y; Hiratsuka Y; Hiragi S; Yamada M
    PLoS One; 2015; 10(7):e0133628. PubMed ID: 26214804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
    Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
    Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?
    Trevithick J; Massel D; Robertson JM; Tomany S; Wall R
    Ophthalmic Epidemiol; 2004 Dec; 11(5):337-46. PubMed ID: 15590581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic Short-Term Cost Model for Stereotactic Radiotherapy of Neovascular AMD].
    Neubauer AS; Reznicek L; Minartz C; Ziemssen F
    Klin Monbl Augenheilkd; 2016 Aug; 233(8):951-7. PubMed ID: 27130973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of age-related macular degeneration.
    Schmier JK; Jones ML; Halpern MT
    Pharmacoeconomics; 2006; 24(4):319-34. PubMed ID: 16605279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epidemiology of age-related macular degeneration].
    Brandl C; Stark KJ; Wintergerst M; Heinemann M; Heid IM; Finger RP
    Ophthalmologe; 2016 Sep; 113(9):735-45. PubMed ID: 27541733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Options for Age-Related Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System.
    Elias FT; Silva EN; Belfort R; Silva MT; Atallah ÁN
    PLoS One; 2015; 10(10):e0139556. PubMed ID: 26457416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community.
    Evans JR; Fletcher AE; Wormald RP
    Ophthalmology; 2004 Mar; 111(3):513-7. PubMed ID: 15019328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.